

UK NEQAS

Leucocyte Immunophenotyping

www.ukneqasli.co.uk



New Information for 2022/2023

EQA Programmes for
Molecular Haemato-Oncology

EQAInternational
Working in partnership with UK NEQAS LI

www.eqainternational.com

New Information for 2022/2023

EQA Programmes for Molecular Haemato-Oncolog

Chronic Lymphocytic Leukaemia Gene Panels (Pilot - Not Accredited) will expand to encompass a broader range of lymphoid malignancies which will necessitate a name change to **Lymphoid Gene Panels* (Pilot - Not Accredited)**.

Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels (Pilot - Not Accredited) will expand to encompass a broader range of myeloid malignancies which will necessitate a name change to **Myeloid Gene Panels* (Pilot - Not Accredited)**.

Myeloproliferative Neoplasm Gene Panels (Pilot - Not Accredited) will be renamed **Myeloproliferative Neoplasm Diagnostic Testing (Pilot - Not Accredited)** and will be limited to testing of *JAK2* p.Val617Phe, *JAK2* exon 12, *CALR* exon 9 and *MPL* exon 10 variants. Extended NGS panel data will be incorporated into the new **Myeloid Gene Panels (Pilot - Not Accredited)** programme - see above.

We will be launching a new programme - Measurable Residual Disease for Acute Myeloid Leukaemia by Molecular Methods (Pilot - Not Accredited), to assess laboratories' ability to accurately detect and quantify MRD using the fusion genes: t(8;21) *RUNX1::RUNX1T1*, inv(16) *CBFB::MYH11*, and t(15;17) *PML::RARA* and known genomic variants in exon 12 of the *NPM1* gene.

Minor programme updates:

- In the ***FLT3* Mutation Status** Programme, one additional sample per trial distribution will be issued for *FLT3* tyrosine kinase domain (TKD) (p.Asp835/p.Ile836) analysis.
- We will be increasing the number of rearrangements within the repertoire of the ***BCR::ABL1* and AML Translocation programme**. We will issue one educational sample per distribution in the 2022/2023 registration period.

SEE WEBSITE FOR FULL INFORMATION ON ALL OF THE ABOVE CHANGES AND TO VIEW ALL OF OUR MOLECULAR HAEMATO-ONCOLOGY PROGRAMMES

*There will be two distributions per annum, one will focus on summarising the variants detected by participants (including methodological aspects) and the other will additionally provide educational elements related to variant interpretation/classification.

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI

Pegasus House
4th Floor Suite
463a Glossop Road
Sheffield S10 2QD
United Kingdom

Tel: +44 (0)114 2673600
Fax: +44 (0)114 2673601

email: admin@ukneqasli.co.uk
www.ukneqasli.co.uk

Please note that if your participation with UK NEQAS LI is via a non-UK distributor (and is outside of the UK) you should contact them directly for details of how to register.

If you are enquiring from outside of the UK your registration will be managed by EQA International Ltd.